Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 1/Phase 2NCT04068610COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRCMedImmune LLC · Metastatic Microsatellite-stable Colorectal CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 10, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT05039840Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusSanofi · Systemic Lupus ErythematosusActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Sep 4, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06267729Study of AZD0754 in Participants With Metastatic Prostate CancerAstraZeneca · Metastatic Prostate CancerRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 24, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT07011706ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic DermatitisAclaris Therapeutics, Inc. · Atopic DermatitisActive, not recruitingACRSLead
- Enrollment
- Locked
- Primary completion
- Sep 21, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT05831176A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic...Regeneron Pharmaceuticals · Eosinophilic Gastritis (EoG)Active, not recruitingREGNLeadSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 23, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsApollomics Inc. · Solid TumorsRecruitingAPLMLead
- Enrollment
- Locked
- Primary completion
- Mar 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT03476681Study of NEO-201 in Solid Tumors Expansion CohortsPrecision Biologics, Inc · Non Small Cell Lung CancerActive, not recruitingDTILLead
- Enrollment
- Locked
- Primary completion
- Jun 17, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT03989414A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination...Celgene · Multiple MyelomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04999969Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or...AstraZeneca · Locally Advanced or Metastatic Solid TumoursActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 7, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT05094336A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Amgen · Advanced MTAP-null Solid TumorsActive, not recruitingAMGNLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT05095727A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)ModernaTX, Inc. · Glycogen Storage DiseaseActive, not recruitingMRNALead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05853575Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Mirati Therapeutics Inc. · Advanced CancerActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Oct 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06593522A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)Amgen · MTAP-deleted NSCLCActive, not recruitingAMGNLead
- Enrollment
- Locked
- Primary completion
- Oct 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06812078A Study of TAK-360 in Adults With Idiopathic HypersomniaTakeda · Idiopathic HypersomniaRecruitingTAKLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06952699A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)Takeda · Narcolepsy Type 2RecruitingTAKLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04745689Study of AZD2811 + Durvalumab in ES-SCLCAstraZeneca · Small-Cell Lung CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jun 18, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT05609578Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationMirati Therapeutics Inc. · Advanced NSCLCActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Sep 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06907511Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic...Sanofi · Pandemic Influenza ImmunizationActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04797000Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion DependenceNovartis Pharmaceuticals · Myelodysplastic SyndromesActive, not recruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Apr 26, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT05588843Dose-finding Study of SAR443122 in Adult Participants With Ulcerative ColitisSanofi · Colitis UlcerativeActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Feb 10, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT06421636A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron...Regeneron Pharmaceuticals · Non-Transfusion Dependent Beta-Thalassemia (NTDT)Active, not recruitingREGNLead
- Enrollment
- Locked
- Primary completion
- Dec 3, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT07222917A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in...AstraZeneca · Chronic Kidney Disease and HypertensionActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 10, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06122779Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection...Bristol-Myers Squibb · Heart FailureActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Dec 14, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT07184632A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or ObesityNovo Nordisk A/S · OverweightActive, not recruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Dec 14, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06387342Namodenoson Treatment of Advanced Pancreatic CancerCan-Fite BioPharma · Pancreatic AdenocarcinomaRecruitingCANFLead
- Enrollment
- Locked
- Primary completion
- Jul 15, 2026Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 2 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.